Some drugmakers are worried that the pace of drug approvals could slow after Janet Woodcock retires as director of the FDA's Center for Drug Evaluation and Research, according to this article. Woodcock is at least a year away from leaving that role. FDA divestment rules and other obstacles can make it hard to find a successor, she said.

Full Story:

Related Summaries